These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24081029)

  • 1. Inactive ERBB receptors cooperate with reactive oxygen species to suppress cancer progression.
    Hart MR; Su HY; Broka D; Goverdhan A; Schroeder JA
    Mol Ther; 2013 Nov; 21(11):1996-2007. PubMed ID: 24081029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer.
    Maisel SA; Broka D; Atwell B; Bunch T; Kupp R; Singh SK; Mehta S; Schroeder J
    J Transl Med; 2019 Jun; 17(1):201. PubMed ID: 31215437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
    Choi BK; Fan X; Deng H; Zhang N; An Z
    Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells.
    Khan IH; Zhao J; Ghosh P; Ziman M; Sweeney C; Kung HJ; Luciw PA
    Assay Drug Dev Technol; 2010 Feb; 8(1):27-36. PubMed ID: 20035613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ErbB receptor tyrosine kinase inhibitors as therapeutic agents.
    Anderson NG; Ahmad T
    Front Biosci; 2002 Sep; 7():d1926-40. PubMed ID: 12161338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.
    Stoll SW; Kansra S; Peshick S; Fry DW; Leopold WR; Wiesen JF; Sibilia M; Zhang T; Werb Z; Derynck R; Wagner EF; Elder JT
    Neoplasia; 2001; 3(4):339-50. PubMed ID: 11571634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.
    Kovacevic Z; Menezes SV; Sahni S; Kalinowski DS; Bae DH; Lane DJ; Richardson DR
    J Biol Chem; 2016 Jan; 291(3):1029-52. PubMed ID: 26534963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A peptide antagonist of the ErbB1 receptor inhibits receptor activation, tumor cell growth and migration in vitro and xenograft tumor growth in vivo.
    Xu R; Povlsen GK; Soroka V; Bock E; Berezin V
    Cell Oncol; 2010 Jan; 32(4):259-74. PubMed ID: 20364069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding.
    Kleiman LB; Maiwald T; Conzelmann H; Lauffenburger DA; Sorger PK
    Mol Cell; 2011 Sep; 43(5):723-37. PubMed ID: 21884975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
    Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
    Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.
    Kedrin D; Wyckoff J; Boimel PJ; Coniglio SJ; Hynes NE; Arteaga CL; Segall JE
    Clin Cancer Res; 2009 Jun; 15(11):3733-9. PubMed ID: 19458057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
    Asp N; Pust S; Sandvig K
    Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
    McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
    Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
    Shin DH; Jo JY; Han JY
    Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling.
    Menezes SV; Sahni S; Kovacevic Z; Richardson DR
    J Biol Chem; 2017 Aug; 292(31):12772-12782. PubMed ID: 28615452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging.
    Macdonald-Obermann JL; Adak S; Landgraf R; Piwnica-Worms D; Pike LJ
    J Biol Chem; 2013 Oct; 288(42):30773-30784. PubMed ID: 24014028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.